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ABSTRACT
 لتقدمي حملة عامة عن مدى ارتفاع نسبة الدهون في املرضى الذين:األهداف
 وكيفية استخدام العالج بخفض الدهون،جدا
ً يعانون من مخاطر عالية
.) في بيئة واقعيةLLT(
 مت جمع املعطيات، في هذه الدراسة املالحظة متعددة املراكز:الطريقة
 املستقر في اململكةACS  أوCHD  الذين عوجلوا بدواءLLT من مرضى
18  مت إدراج األفراد البالغني من.م2014 م و2013 العربية السعودية بني
 مسجل إما قبل زيارة الطبيب،عا ًما وكان لديهم ملف كامل للدهون
 ساعة من دخول املستشفى24 ) أو في غضونCHD األساسي (مرضى
.)ACS (مرضى
 مع597  و، مريضا في الدراسة737  اشتملت الدراسة على:النتائج
 عدد قليل من املرضى في أي من.ACS  مع140  مستقر وCHD
 والذي،  ديسيلتر/ > ملغ70  منLDL-C املجموعتني لديهم مستوى
 على11.4٪  و24.3٪( ًيتم دعمه للمرضى املعرضني ملخاطر عالية جدا
)CHD(  دل/  مغ19.0  املتوسط وكانت املسافات لهذه القيمة.)التوالي
 مت استخدام جرعات منخفضة من.)ACS(  ديسيلتر/  ملغ25.0 و
ACS  وCHD  يوم ل/  ملغ24  و31( العقاقير املخفضة للكوليسترول
 بعد دخولACS  مع تكثيف احلد األدنى فقط ملرضى، ) على التوالي،
.) يوم في املتابعة/  مجم41( املستشفى
 املوصى بها سيئة للمرضىLDL-C  كان حتقيق مستويات:اخلامتة
 كانت شدة.ACS الذين يعانون من أمراض الشرايني التاجية املستمرة أو
 مما يشير إلى نطاق كبير لتكثيف عالج هؤالء املرضى، الستاتني منخفضة
.عالية املخاطر
Objectives: To provide an overview of the extent of
hyperlipidemia in very high-risk patients, and how
lipid-lowering therapy (LLT) is used in a real-world
setting.
Methods: In this multicenter observational study,
data were collected from LLT-treated patients with
stable CHD or an ACS in Saudi Arabia between 2013
and 2014. Individuals were included if they were >18
years and had a full lipid profile available, recorded

OPEN ACCESS

either prior to the baseline physician visit (CHD
patients) or within 24-hours of admission to hospital
(ACS patients).
Results: A total of 737 patients were included in the
study, 597 with stable CHD and 140 with ACS. Few
patients in either group had an LDL-C level of <70
mg/dl, which is advocated for very high-risk patients
(24.3% and 11.4%, respectively). The median
distances to this value were 19.0 mg/dl (CHD) and
25.0 mg/dl (ACS). Low doses of statins were being
utilized (31 and 24 mg/day for CHD and ACS,
respectively), with only minimal intensification for
the ACS patients after hospital admission (41 mg/day
at follow-up).
Conclusions: Achievement of recommended LDL-C
levels was poor for patients with stable CHD or an
ACS. Statin intensity was low, indicating huge scope
for intensifying the treatment of these very high-risk
patients.
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I

t is well-established that patients with coronary heart
disease (CHD) are at very high risk for experiencing
an adverse cardiovascular event. Such risk can be
reduced by careful management of associated risk
factors, including hypertension, diabetes mellitus, and
dyslipidemia.1,2 Lipid abnormalities, such as high levels
of low-density lipoprotein cholesterol (LDL-C) or
triglycerides, and low levels of high-density lipoprotein
cholesterol (HDL-C), are known to be highly prevalent
in patients with CHD.3 Indeed, in a recent study of
CHD patients in Saudi Arabia, 76.7% were found to
have dyslipidemia.4 The benefits of reducing LDL-C
levels in particular have been extensively studied in the
context of decreasing the occurrence of cardiovascular
events. Indeed, it has been shown that a reduction in
LDL-C of approximately 39 mg/dl (1 mmol/l) could
decrease the 5-year rate of major vascular events by
approximately a fifth.
Evidence-based guidelines for the treatment of
dyslipidemia from the European Society of Cardiology
(ESC) and the European Atherosclerosis Society
(EAS) advocate a target LDL-C level of <70 mg/dl
(1.81 mmol/l) for patients at very high cardiovascular
risk, such as those with established CHD.5 Lipidlowering therapies (LLTs) such as statins have been
shown to effectively reduce levels of LDL-C; however,
despite their widespread use, significant numbers of
high risk CHD patients fail to achieve target levels. In
the Middle Eastern cohort of the first Dyslipidemia
International Study (DYSIS), only 30.5% of the
statin-treated group at highest cardiovascular risk had
an LDL-C level below 70 mg/dl.6 Results from the
Arabian Gulf countries included in the Centralized
pan-Middle East Survey on the Undertreatment of
Hypercholesterolemia (CEPHEUS) showed 31.9%
achievement of the same LDL-C target for the very
high-risk patients being treated with LLT.7 The
EUROASPIRE studies have demonstrated increasing

Disclosure. Gitt has received honoraria from Merck &
Co., Inc., Kenilworth, NJ, USA for contribution to the
DYSIS study. M. Horack reports that his institution
received funding for recruitment and biostatistics for
the DYSIS registry. A Vyas was a full time employee of
Rutgers University which received funding from Merck
& Co., Inc., Kenilworth, NJ USA at the time this
work was conducted. (Dr. Vyas is currently employed
by the University of Rhode Island). Atif Bin Shafi
Shafiurrehman, S Wajih, B. Ambegaonkar, P. Brudi, D.
Lautsch, and C. Baxter are employees of Merck & Co.,
Inc., Kenilworth, NJ USA or Merck Sharp & Dohme.
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statin use in patients with CHD over the last decades;
however, in their most recent analysis, only 19.5% of
patients had an LDL-C level below 70 mg/dl.8 In a
single-center study in Saudi Arabia, few CHD patients
had a recent lipid profile recorded in their medical
notes, indicating poor monitoring of hyperlipidemia in
these high-risk patients.9
In order to obtain details on the management of
cholesterol in patients with CHD, and to evaluate
current treatment practices, DYSIS II was initiated.10
This was a multinational, observational study
investigating lipid abnormalities in patients with either
stable CHD or presenting with an acute coronary
syndrome (ACS). With the use of standardized
methodology, the prevalence of lipid abnormalities, and
predictors of LDL-C target attainment, was evaluated
in patients from countries throughout the world.
Here, we present the results collected in Saudi Arabia,
providing an overview of the extent of hyperlipidemia
in these very high-risk patients, and how LLT is used in
a real-world setting.
Methods. Patients were enrolled at 4 centers within
Saudi Arabia from December 2013 to October 2014.
Individuals with either stable CHD or those admitted
to the hospital with an ACS were included if they
were over 18 years of age and had a full lipid profile
available. Acute coronary syndrome was defined as an
ST-segment elevation myocardial infarction (STEMI)/
left bundle branch block myocardial infarction (LBBB
MI), non-ST-segment elevation myocardial infarction
(NSTEMI), or unstable angina (UA) at the time of
hospital admission. For patients with CHD, the lipid
profile was obtained from the last blood test within
the 12 months prior to the baseline physician visit; for
patients with an ACS, the lipid profile was recorded
within 24 hours of admission to the hospital. Patients
were included in the present analysis if they had
been receiving LLT for at least 3 months prior to the
latest lipid test. Patients were excluded if they were
participating in a clinical trial at the same time as the
study, and for the ACS patients, if they died during the
hospital stay. For CHD patients, data were collected at
the baseline physician visit. For ACS patients, data were
collected on admission to the hospital and at 4 months
(±15 days) post-admission.
All included patients provided written informed
consent. The study received ethical approval from
the relevant national and regional committees at each
participating center, and was carried out in accordance
with the Declaration of Helsinki and its amendments.
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Data were recorded on a standardized case
report form (CRF) and later entered into a central
web-based database maintained at the Institut für
Herzinfarktforschung, Ludwigshafen, Germany.
Demographic and clinical variables were collected at
baseline, including age, gender, and body mass index
(BMI); presence of hypertension or type 2 diabetes
mellitus; a sedentary lifestyle or smoking; a history of
CHD, peripheral artery disease (PAD), chronic renal
failure (CRF), or chronic kidney disease (CKD); a
prior MI or stroke (ischemic or hemorrhagic); and any
family history of CHD. Obesity was defined as BMI
>30 kg/m². Diabetes was defined as current treatment
for diabetes, a previous diagnosis of diabetes, or a fasting
plasma glucose level of ≥126 mg/dl. Hypertension was
defined as current treatment, a previous diagnosis, or
having blood pressure of >140/90 mm Hg. A sedentary
lifestyle was defined as <20-30 minutes of walking on
<3-4 days per week. Use of cardiovascular medications
(beta-blockers, calcium channel blockers, diuretics,
ACE inhibitors, antiplatelet agents) and laboratory
values of HbA1c and blood glucose at admission were
also documented. A full lipid profile, which included
measurement of serum levels of total cholesterol (TC),
LDL-C, HDL-C, non-HDL-C, and triglycerides was
recorded at baseline. For the ACS patients, any further
lipid profiles available from the follow-up period were
also collected.
For ACS patients, pre-ACS cardiovascular risk status
was determined according to the ESC/EAS guidelines,
and targets for LDL-C for very high-risk patients
were defined as <70 mg/dL, high-risk <100 mg/dL,
moderate-risk <115 mg/dL, and low-risk <130 mg/dL.5
As shown in the guidelines, very high- and high-risk
patient groups have clearly set target values based on
comorbidity, while additional risk factors or markers
such as obesity or high C-reactive protein (CRP) are
taken into account for moderate and low cardiovascular
risk. Low-density lipoprotein cholesterol goal attainment
was judged based on lipid values at admission, reflecting
the pre-admission lipid levels. The median distance to
the LDL-C target was calculated for patients who had
not attained this level on the date of the lipid profile.
Details of the LLT that each patient was being treated
were documented. The following classes of LLT were
assessed: statin monotherapy, non-statin monotherapy,
statin plus ezetimibe, and statin plus other non-statin
therapy (other non-statins included nicotinic acids,
fibrates, omega-3 fatty acids, and other less common
agents). The statins assessed were atorvastatin, fluvastatin,
lovastatin, pravastatin, pitavastatin, rosuvastatin, and
simvastatin. Atorvastatin dose equivalents were based

on clinical trial data regarding the LDL-C-lowering
efficacy of various statins.
For ACS patients, at 4 months (±15 days) postadmission, any lipid profiles obtained since hospital
discharge were collected. The median distance to the
LDL-C target was calculated for patients who had not
attained the LDL-C target on the date of the lipid profile.
Any occurrence of cardiovascular-related adverse events
(rehospitalization, MI, stroke, percutaneous coronary
intervention [PCI], or coronary artery bypass grafting
[CABG]) during the follow-up period was recorded.
These outcomes were not mutually exclusive.
Statistics analysis. Data are presented as means with
standard deviations (SD), medians with interquartile
ranges (IQR), or absolute values with percentages.
Statistical significance was determined using the
Chi-squared test or the Mann-Whitney-Wilcoxon test.
Multivariate logistic regression was conducted in
order to identify any predictors of a patient having
an LDL-C level below 70 mg/dl. The covariates were
age, female gender, obesity, current smoking, sedentary
lifestyle, stable angina, CKD, type 2 diabetes mellitus,
history of congestive heart failure [CHF], hypertension,
and statin dose [atorvastatin dose equivalent]).
Data were analyzed using SAS version 9.3 (Cary, NC,
USA) and a p-value <0.05 was considered statistically
significant.
Results. Five hundred and ninety-seven LLT-treated
patients with stable CHD were recruited (Table 1). The
mean age of these subjects was 62.5 (±9.8) years and
79.2% were male. Obesity was recorded for 58.8% of the
population. Other cardiovascular risk factors included
current smoking (16.8%), a sedentary lifestyle (69.4%),
and a family history of CHD (21.6%). Hypertension
was highly prevalent, being found in 76.5% of patients.
Greater than 50% stenosis was observed by coronary
angiography for 45.4% of patients, and by cardiac
computed tomography for 1.2%. A total of 39.5% of
patients had previously undergone PCI, 20.9% had
undergone CABG, and 7.2% had experienced an ACS
>3 months prior to the physician visit.
One hundred and forty LLT-treated patients
admitted to the hospital with an ACS were enrolled
in the study (Table 1). The mean age of these subjects
was 62.9 (±8.6) years and 77.1% were male. Obesity
was recorded for 79.3% of the population. A high
proportion (75%) reported a sedentary lifestyle, while
current smoking (41.4%) and a family history of CHD
(17.3%) were also common. The majority of patients
had hypertension (74.3%), and many had type 2
diabetes mellitus (54.3%). The primary ACS diagnosis
was STEMI for 65% of patients and a NSTEMI for
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16.4%. The remaining patients (18.6%) were diagnosed
with UA.
Lipid profile at time of latest lipid test. For the CHD
patients, the mean LDL-C level was 84.2 (±23.9) mg/dl,
with only 24.3% having a value below the ESC/EAS
target of 70 mg/dl (Table 2).
Multivariate logistic regression identified type
2 diabetes mellitus as being predictive of achieving
Table 1 - Characteristics at baseline of 140 lipid-lowering therapiestreated patients admitted to the hospital with an ACS.
Characteristics
Age (years)
Male (%)

Stable CHD
n=597
62.5 ± 9.8

ACS
n=140
62.9 ± 8.6

79.2 (473/597)

77.1 (108/140)

30.9 (28.0, 33.4)

33.1 (30.8, 35.3)

BMI >30 kg/m2 (%)

58.8 (351/597)

79.3 (111/140)

SBP (mmHg)

130 (122, 135)

130 (126, 136)

DBP (mmHg)

75 (68, 81)

78 (69, 82)

BMI (kg/m2)

CV risk factors (%)
Current smoker

16.8 (100/597)

41.4 (58/140)

Sedentary lifestyle

69.4 (414/597)

75.0 (102/136)

Family history of CHD

21.6 (123/569)

17.3 (23/133)

Comorbidities (%)
Type 2 diabetes mellitus

55.8 (333/597)

54.3 (76/140)

Hypertension

76.5 (457/597)

74.3 (104/140)

CKD

7.7 (46/597)

5.0 (7/140)

Prior stroke*

4.3 (25/576)

5.7 (8/140)

History of PAD

3.9 (22/569)

7.9 (11/140)

Data presented as mean ± standard deviation, median (interquartile
range), or percentage (n/N). *includes ischemic and hemorrhagic stroke.
CHD - coronary heart disease, ACS - acute coronary syndrome,
BMI - body mass index, SBP - systolic blood pressure, DBP - diastolic
blood pressure, CV - cardiovascular, CKD - chronic kidney disease, PAD
- peripheral artery disease.

an LDL-C level of <70 mg/dl (adjusted odds ratio
(AOR): 1.81; 95% confidence interval (CI): 1.14-2.89;
p=0.01), while a sedentary lifestyle (AOR: 0.35; 95%
CI: 0.30-0.55, p<0.0001) lowered the likelihood of
target value attainment (Table 3).
For the ACS patients, 11.1% (15/135) of those
at very high risk and 50% (1/2) of those at high risk,
but none of those at moderate risk (0/3), according to
pre-ACS risk level, were at their respective LDL-C target
at hospital admission. As per the ESC/EAS guidelines,
all patients were classed as being at very high risk on
admission, owing to their presentation with an ACS.5
The mean LDL-C value for the ACS patients, measured
within 24 hours of admission, was 103 (±42.9) mg/dl
(Table 2).
Only 11.4% of this population had an LDL-C level
of <70 mg/dl. The median distance to this value was
25.0 (19.0, 50.0) mg/dl. The median HDL-C level was
35.0 (34.0, 43.0) mg/dl, the median non-HDL-C level
was 162.0 (130.0, 184.5) mg/dl, the mean TC level was
198.5 (±61.0) mg/dl, and the median triglyceride level
was 115.0 (106.0, 124.0) mg/dl. Multivariate logistic
regression using data collected at hospital admission,
found that an age equal or greater to 70 years was
associated with an increased likelihood of having
an LDL-C level of <70 mg/dl (AOR: 8.16; 95% CI
1.79-37.30; p=0.0068) (Table 3).
During the 4-month follow-up period, a lipid profile
was collected for 21 of the patients. Of these, none had
an LDL-C level of <70 mg/dl at admission and one
(4.8%) had reached this target by the follow-up point.
Lipid-lowering therapy. Of the stable CHD patients,
84.3% were on statin monotherapy, while 14.6% were
on a combination of a statin and ezetimibe, and 1%
on a combination of a statin and other non-statin
(Table 4). Atorvastatin was the most commonly

Table 2 - Baseline lipid profile of both cohort of ACS and CHD enrolled in hyperlipidemia in Saudi
Arabia study.
Lipid profile
LDL-C (mg/dl); mean ± SD
HDL-C (mg/dl); median (IQR)
Non-HDL-C (mg/dl); median (IQR)
TC (mg/dl); mean ± SD
Triglycerides (mg/dl); median (IQR)

CHD
n=597
84.2 ± 23.9

ACS
n=140
103.0 ± 42.9

35.0 (32.0, 42.0)

35.0 (34.0, 43.0)

127.0 (93.0, 166.0)

162.0 (130.0, 184.5)

167.7 ± 42.0

198.5 ± 61.0

124.0 (105.0, 142.0)

115.0 (106.0, 124.0)

LDL-C <70 mg/dl†

24.3 (145/597)

11.4 (16/140)

Distance to LDL-C <70 mg/dl (mg/dl)‡

19.0 (7.0, 31.0)

25.0 (19.0, 50.0)

*CHD patients: last recorded lipid profile prior to physician visit, ACS patients: within 24 h of
admission for ACS event. †ECS/EAS guidelines for very high-risk patients.5 ‡For patients not at target.
LDL-C - low-density lipoprotein cholesterol,
HDL-C - high-density lipoprotein cholesterol, TC - total cholesterol
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Table 3 - Multiple logistic regression model for an LDL level of <70 mg/dl at baseline in both cohort of ACS
and CHD enrolled in hyperlipidemia in Saudi Arabia study.
Variable

CHD patients

ACS patients

OR (95% CI)

P-value

OR (95% CI)

Age ≥70 years

1.17 (0.71-1.92)

0.53

8.16 (1.79-37.30)

P-value
0.0068

Female gender

1.07 (0.64-1.81)

0.79

0.30 (0.05-1.88)

0.20

BMI > 30 kg/m2

0.71 (0.46-1.08)

0.11

1.27 (0.31-5.22)

0.74

Current smoking

0.82 (0.42-1.57)

0.54

0.85 (0.20-3.50)

0.82

Sedentary lifestyle

0.35 (0.30-0.55)

<0.0001

0.27 (0.07-1.07)

0.0624

Stable angina

0.986 (0.55-1.76)

0.96

0.65 (0.11-3.94)

0.64

Type 2 diabetes

1.81 (1.14-2.89)

0.01

0.47 (0.13-1.73)

0.26

Hypertension

0.70 (0.44-1.13)

0.14

0.65 (0.18-2.34)

0.51

Statin dose
(atorvastatin eq.
mg/day)

1.01 (0.998-1.02)

0.11

1.01 (0.97-1.06)

0.60

BMI - body mass index, the model includes all displayed variables, which were selected based on clinical
relevance. LDL-C - low-density lipoprotein cholesterol, CHD - coronary heart disease, ACS - acute coronary
syndrome, BMI - body mass index
Table 4 - Lipid-lowering therapy at baseline in both cohort of ACS and CHD enrolled in hyperlipidemia in Saudi Arabia study.
Lipid-lowering therapy

Stable CHD*
N=597

ACS
Hospital admission
n=140

4-month follow-up
n=139

Statin therapy (%)

99.8 (596/597)

92.7 (139/140)

100.0 (139/139)

Atorvastatin

63.8 (381/597)

52.9 (74/140)

90.6 (126/139)

Fluvastatin

0.2 (1/597)

0.0 (0/140)

0.0 (0/139)

Lovastatin

0.0 (0/597)

0.0 (0/140)

0.0 (0/139)

Pitavastatin

0.2 (1/597)

0.0 (0/140)

0.0 (0/139)

Pravastatin

0.0 (0/597)

0.7 (1/140)

0.0 (0/139)

Rosuvastatin

8.7 (52/597)

4.3 (6/140)

7.9 (11/139)

Simvastatin
Statin daily dose – atorvastatin eq. (mg/day)†
Statin monotherapy (%)
Non-statin monotherapy (%)
Statin + ezetimibe
Statin + other non-statin

27.0 (161/597)

39.3 (55/140)

1.4 (2/139)

31 ± 18 (n = 597)

24 ± 13 (n = 140)

41 ± 15 (n = 139)

84.3 (503/597)

84.3 (118/140)

60.4 (84/139)

0.2 (1/597)

0.7 (1/140)

0.0 (0/139)

14.6 (87/597)

12.9 (18/140)

38.8 (54/139)

1.0 (6/597)

2.1 (3/140)

0.7 (1/139)

*Lipid-lowering therapy (LLT) at time of latest lipid profile; †dose equivalents calculated.11 Data presented as mean ± standard deviation, or
percentage (n/N). CHD - coronary heart disease, ACS - acute coronary syndrome

used statin (63.8%), followed by simvastatin (27%),
and rosuvastatin (8.7%). When statin potency was
normalized to Atorvastatin, the mean daily dosage
was calculated to be 31 ± 18 mg. Of the ACS patients,
84.3% were on statin monotherapy, 12.9% were on a
combination of a statin and ezetimibe, and 2.1% on a
combination of a statin and other non-statin. Atorvastatin
was the most commonly used statin (52.9%), followed

by simvastatin (39.3%), and rosuvastatin (4.3%).
The mean atorvastatin equivalent daily dosage was
24 ± 13 mg. At the 4-month follow-up point, 60.4%
of the ACS patients were on statin monotherapy, while
38.8% were on a combination of statin and ezetimibe.
The prescription patterns of the different statins differed
from baseline, with a higher proportion of patients
receiving Atorvastatin (52.9% versus 90.6%) and a
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lower proportion receiving simvastatin (39.3% versus
1.4%). The mean Atorvastatin equivalent daily statin
dosage had increased from 24 ± 13 mg at admission to
41 ± 15 mg at 4 months.
Events during follow-up for ACS patients. None of
the ACS patients died during the 4-month follow-up
period. There was no occurrence of MI or stroke, and
no patients underwent PCI or CABG. Only 2 of the
patients that were treated with LLT prior to admission
required rehospitalization. There was no increased
untoward effects reported with the increase of the statin
dose over time.
Discussion. Dyslipidemia International Study
II was established in order to specifically address
hyperlipidemia in patients with either stable CHD or
ACS, and to evaluate their treatment. Patients from
Saudi Arabia, a country with alarming prevalence of
cardiovascular risk factors, attainment of an LDL-C
level of <70 mg/dl was poor. Furthermore, for the
patients admitted to the hospital because of an ACS,
LLT intensification was inadequate.
As in the rest of the world, hyperlipidemia is
becoming more prevalent in Saudi Arabia as the average
age and income of the population increase.12 In DYSIS,
it was shown that only 26.4% of Saudi patients classed
as being at very high cardiovascular risk had an LDL-C
level of <70 mg/dl, despite being treated with statins.13
A high level of under-treatment of these patients was
indicated, a finding that was also reported for the
Arabian Gulf cohort of CEPHEUS.7
Comorbidities and cardiovascular risk factors were
highly prevalent in both the patients with stable CHD
and those admitted to the hospital for ACS. Obesity was
extremely common, in particular for the ACS patients
(79.3%). In comparison to the DYSIS II data for the
Middle East and Africa region combined (Manuscript
in preparation), almost 30% of the ACS patients from
Saudi Arabia were classed as obese. This is in agreement
with data presented by Yatsuya et al14 where Saudi
Arabia was shown to have one of the highest levels
of overweight and obesity in the East Mediterranean
region. A sedentary lifestyle was also common (69.4%
and 75% of LLT-treated CHD and ACS patients,
respectively), as was smoking (16.8% and 41.4%,
respectively), suggesting that better patient education
would be beneficial for improving these modifiable risk
factors.15 Similar to previous studies in patients at high
cardiovascular risk, hypertension and diabetes mellitus
were noted for large proportions of patients.4,7,8
For the CHD patients, less than a quarter (24.3%)
attained LDL-C <70 mg/dl, despite the finding of a
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relatively low mean LDL-C value in comparison to the
average values quoted in other studies.4,7 Poor LDL-C
target attainment was also reported for the very high
risk LLT-treated patients in the Middle East cohort
of DYSIS and the Arabian Gulf countries included in
CEPHEUS, with 30.5% and 31.9% of these patients,
respectively, achieving a level of <70 mg/dl.6,7 We found
that the distance to target for those not at goal was quite
small, indicating that even small reductions in LDL-C
levels would greatly increase target attainment. This is
corroborated by the high proportion of CHD patients
(68%) achieving a level of <100 mg/dl in a previous
study in Saudi Arabia.9 After multivariable analysis, the
only factors that were found to be associated with an
LDL-C level below 70 mg/dl were a sedentary lifestyle,
which decreased the likelihood, and type 2 diabetes,
which increased the likelihood. In CEPHEUS, Arafah et
al7 also identified a history of diabetes as being predictive
of target achievement. A potential explanation for this
finding is that patients with diabetes may be more aware
of the seriousness of their health situation and so might be
more adherent to pharmacological therapy and lifestyle
improvements. Furthermore, they would be likely to
have greater contact with physicians (cardiologists and
endocrinologists). Al Shammeri et al9 found that a high
proportion of the stable CHD patients included in their
study did not have a recent LDL-C level documented in
their medical notes. It therefore appears that increased
attention to lipid testing may have a positive effect on
target attainment in CHD patients.
Low-density lipoprotein cholesteroltarget attainment
according to pre-ACS risk level was extremely poor for
the ACS patients, reaching just over 11% for those at
very high risk. In contrast to the patients with stable
CHD, the only factor included in the multivariable
analysis that was found to be associated with ACS
patients displaying an LDL-C level of <70 mg/dl at
admission was an age of 70 years or above.
The low levels of target achievement suggest highly
ineffective use of LLT in these very high risk patients.
While all subjects were being treated with LLT, the
mean atorvastatin equivalent daily dose was only 31 mg
for the stable CHD patients and 24 mg for the ACS
patients at admission. While the dosage by the 4-month
follow-up point had increased to 41 mg for the ACS
patients, this is still only a medium intensity. Nicholls
et al16 reported significant coronary plaque regression
when intensive Atorvastatin (80 mg/day) or rosuvastatin
(40 mg/day) therapy was prescribed to patients with
CHD.16 Furthermore, in the Pravastatin or Atorvastatin
Evaluation and Intensive Therapy-Thrombolysis in
Myocardial Infarction-22 (PROVE IT–TIMI 22),
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patients with an ACS who were treated with intensive
statin therapy were found to have a lower likelihood of
death or a major cardiovascular event in comparison to
the patients that received standard therapy.17 Similar
advantages of intensive LLT were found in the GWTG
database and the Translational Research Investigating
Underlying Disparities in Acute Myocardial Infarction
Patients’ Health Status (TRIUMPH) study.18 A number
of other trials have also demonstrated advantages in
terms of lipid-lowering and occurrence of cardiovascular
adverse events when more intensive statin treatment is
prescribed.19 The majority of these studies utilized an
Atorvastatin dose of 80 mg as the intensive arm, which
highlights the low average doses used for the patients in
the present analysis. In the Middle Eastern CEPHEUS
patients, although exact normalized statin doses were
not reported, the majority of patients were being treated
with the equivalent of ≤30 mg of atorvastatin per day.7 In
DYSIS, which was carried out in 2011-2012, the most
commonly prescribed statin dose for the very high risk
patients in the Middle East countries was equivalent to
20 mg per day.6 The increase in statin dose from DYSIS
to DYSIS II may indicate improvement in the way in
which these drugs are used for managing LDL-C levels
in CHD patients in Saudi Arabia; however, there is
clearly room for treatment intensification, in particular
for patients who have experienced an ACS.
The addition of a non-statin agent to statin
monotherapy is an alternative method to intensify LLT
for very high risk patients. In the Improved Reduction
of Outcomes: Vytorin Efficacy International Trial
(IMPROVE-IT), it was shown that, in patients that
had suffered an ACS, LDL-C levels were reduced to a
greater extent with the use of ezetimibe in combination
with simvastatin (93.8 mg/dl to 53.7 mg/dl during the
trial) than with simvastatin alone (93.8 mg/dl to 69.5
mg/dl during the study).20 The study also demonstrated
a 2% lower rate of the primary endpoint (cardiovascular
death, non-fatal MI, UA requiring hospitalization,
coronary revascularization, or non-fatal stroke)
achievement for the patients receiving combination
therapy. In addition, increased plaque regression has
been demonstrated for combination therapy (ezetimibe
plus rosuvastatin) in comparison to statin monotherapy
(rosuvastatin alone) in patients with CHD.21,22 In the
present study, ezetimibe use was relatively uncommon
at baseline (14.5% and 12.9% for CHD and ACS
patients, respectively); however, by the 4-month
follow-up point, 38.8% of the ACS patients were being
treated with this agent. Interestingly, this is much higher
than the proportions of patients in other Middle Eastern
countries that participated in DYSIS II (Manuscripts in
preparation). Such evidence of treatment intensification

is promising, but there remains a discrepancy between
optimal therapy and that used in the real-world.
One limitation to this analysis is the low number of
ACS patients with a full lipid profile collected during
the acute phase and the follow-up period. This prevents
us from also establishing a true picture of the effects
of changes that were made to the LLT after admission.
Furthermore, no adverse cardiovascular events were
recorded for the ACS patients during the relatively short
follow-up period, and such events were not monitored
in the patients with stable CHD. This prevents us from
evaluating the associations between lipid levels, LLT,
and long-term cardiovascular outcome.
In conclusions, despite the known benefits of
achieving a low level of LDL-C, few patients had
reached the recommended target for individuals with
CHD. While all patients were being treated with LLT
prior to enrolment in the study, the mean daily dosage
was low. Treatment was intensified for the patients who
were admitted to hospital owing to an ACS; however,
the statin dosages remained low. The data indicate that
there is a huge scope for improving the treatment of
hyperlipidemia in high-risk patients in Saudi Arabia.
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